Add articles to your saved list and come back to them any time.<\/p>\n
Pharmaceutical giant Eli Lilly will study its blockbuster diabetes drug Mounjaro in combination with an experimental muscle-loss treatment as it searches for ways to help patients maintain muscle while losing weight.<\/p>\n
The sheer amount of weight patients are shedding from Mounjaro and similar GLP-1 medications, such as Novo Nordisk\u2019s hit obesity drug semaglutide (the active ingredient in Ozempic and Wegovy), has raised concern that it isn\u2019t just fat melting away, but potentially vital muscle and bone that play key roles in regulating metabolism and preventing injury, particularly in older adults.<\/p>\n
<\/p>\n
Goldman Sachs analysts say obesity treatments are poised for a $160 billion market by 2030.<\/span>Credit: <\/span>Alex Ellinghausen<\/cite><\/p>\n Mounjaro is still under regulatory consideration for treating obesity, and many doctors already prescribe it for that purpose. The drug is part of a new generation of therapies that Goldman Sachs analysts have said are poised for a $US100 billion ($160 billion) market by 2030.<\/p>\n Muscle-mass preservation is becoming a hot new area in obesity medicine. Ania Jastreboff, director of the Yale Obesity Research Centre who has led key Mounjaro studies for Lilly, said at a conference that improving the quality \u2014 not just the quantity \u2014 of weight loss was an essential next-step.<\/p>\n Some muscle loss is expected when a person loses weight. Normally, about a quarter of the weight lost comes from lean mass. That\u2019s a problem for anyone shedding kilos, but potentially dangerous for seniors for whom a decline in muscle and bone can reduce mobility and strength and accelerate frailty.<\/p>\n Experts aren\u2019t clear on just how big of a problem this is for older people taking diabetes and weight-loss drugs such as Mounjaro and Wegovy. In a clinical trial of semaglutide, researchers found that on average, people lost about 6.8 kilograms of lean muscle and 10.4 kilograms of fat during a 68-week trial. The average age in that group of people was 52.<\/p>\n Lilly\u2019s clinical development arm, Chorus, will run a trial with BioAge Labs, a California biotechnology company whose experimental drug azelaprag has shown early promise in preventing muscle atrophy in older adults who\u2019ve been on bed rest. Lilly and BioAge will test the combination in a mid-stage study starting in mid-2024. They will also assess whether patients lose more weight than with Mounjaro alone.<\/p>\n BioAge\u2019s drug mimics the action of apelin, a hormone produced during exercise that enhances metabolism and muscle function, but decreases with age. Amgen initially developed the drug for heart failure, but abandoned it after it failed an early trial. BioAge, however, saw azelaprag\u2019s promise in another area \u2013 ageing.<\/p>\n \u201cA lot of benefits seem to be unlocked in an obesity context,\u201d Kristen Fortney, BioAge\u2019s chief executive officer and co-founder, said.<\/p>\n Biotech companies have been struggling to woo investors as high interest rates drive them away from what\u2019s viewed as a risky industry. Fortney sees obesity as a bright spot, particularly as companies such as Lilly and rival Novo Nordisk explore using their weight-loss therapies to treat heart disease and other related conditions.<\/p>\n This isn\u2019t Lilly\u2019s first foray into studying the effects of a muscle mass treatment.<\/p>\n Lilly acquired obesity start-up Versanis Bio for as much as $US2 billion in July for the same reason it\u2019s partnering with BioAge. Versanis\u2019 experimental drug aims to help people lose weight while preserving muscle mass. The company is studying the candidate on its own and in combination with semaglutide. Lilly plans to study the Versanis drug in combination with Mounjaro, which is slated for approval for weight loss by the end of the year.<\/p>\n \u201cLilly is making bold investments to expand our access to external innovation,\u201d Lilly spokeswoman Stefanie Prodouz said in a statement. \u201cWe seek opportunities that both support and complement our areas of expertise.\u201d<\/p>\n